Andere talen Legend Biotech Corporation

Aandelen

LEGN

US52490G1022

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
45,93 ^USD	+4,43%		+3,40%	-23,67%

22/04	CARVYKTI® (ciltacabtagene autoleucel) van Legend Biotech Corporation goedgekeurd door de Europese Commissie voor tweedelijns behandeling van patiënten met recidief en refractair multipel myeloom	CI
19/04	Amerikaanse FDA verplicht etiketupdates voor CAR-T kankertherapieën	RE

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission	23/04
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer	22/04
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22/04
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma	22/04
US FDA mandates label updates on CAR-T cancer therapies	19/04
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug	17/04
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K	16/04
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results	11/04
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval	09/04
Innovative personalised immunotherapy approved for multiple myeloma	08/04
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	08/04
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma	08/04
U.S. FDA approves expanded use of J&J's cancer cell therapy	06/04
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	06/04
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma	06/04
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05/04
U.S. FDA allows expanded use of Bristol Myers' cell therapy	05/04
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report	20/03
Legend Biotech Files Mixed-Securities Shelf Registration	19/03
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report	19/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Legend Biotech Corporation

Aandelen

LEGN

US52490G1022

Andere talen

Filters